CN1910161A - 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型 - Google Patents

1型11－β－羟基甾醇脱氢酶抑制剂的新晶型 Download PDF

Info

Publication number
CN1910161A
CN1910161A CNA2005800031244A CN200580003124A CN1910161A CN 1910161 A CN1910161 A CN 1910161A CN A2005800031244 A CNA2005800031244 A CN A2005800031244A CN 200580003124 A CN200580003124 A CN 200580003124A CN 1910161 A CN1910161 A CN 1910161A
Authority
CN
China
Prior art keywords
crystalline
anhydrate
monohydrate
solid
curve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800031244A
Other languages
English (en)
Chinese (zh)
Inventor
Y·贝雷兹尼特斯基
M·A·哈夫曼
J·E·林奇
赵芒柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1910161A publication Critical patent/CN1910161A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800031244A 2004-01-26 2005-01-21 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型 Pending CN1910161A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53920604P 2004-01-26 2004-01-26
US60/539,206 2004-01-26

Publications (1)

Publication Number Publication Date
CN1910161A true CN1910161A (zh) 2007-02-07

Family

ID=34826043

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800031244A Pending CN1910161A (zh) 2004-01-26 2005-01-21 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型

Country Status (8)

Country Link
US (1) US7875642B2 (cg-RX-API-DMAC7.html)
EP (1) EP1711477A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007519726A (cg-RX-API-DMAC7.html)
CN (1) CN1910161A (cg-RX-API-DMAC7.html)
AU (1) AU2005207925B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553345C (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03023A (cg-RX-API-DMAC7.html)
WO (1) WO2005073200A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2007038452A1 (en) * 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
WO2007082808A2 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-hsd1 inhibitors
AR059355A1 (es) 2006-02-07 2008-03-26 Wyeth Corp Inhibidores de 11-beta hsd1
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
KR101477154B1 (ko) * 2010-10-01 2014-12-29 산동 루예 파마슈티칼 컴파니 리미티드 4-[2-디메틸아미노-1-(1-하이드록시사이클로헥실)에틸]페닐 4-메틸벤조에이트 하이드로클로라이드의 다형체, 이의 제조 방법 및 이의 용도
CN117398398A (zh) 2017-03-06 2024-01-16 云顶新耀新加坡有限公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100860A3 (en) 1997-12-11 2003-03-28 Janssen Pharmaceutica Nv Retinoic acid mimetic anilides, process for their preparation and pharmaceutical compositions containing them
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2003004497A1 (en) 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
CA2474168A1 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) * 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia

Also Published As

Publication number Publication date
US7875642B2 (en) 2011-01-25
EP1711477A4 (en) 2009-06-10
IN2012DN03023A (cg-RX-API-DMAC7.html) 2015-07-31
CA2553345A1 (en) 2005-08-11
CA2553345C (en) 2011-11-15
JP2007519726A (ja) 2007-07-19
WO2005073200A1 (en) 2005-08-11
AU2005207925A1 (en) 2005-08-11
EP1711477A1 (en) 2006-10-18
US20090186928A1 (en) 2009-07-23
AU2005207925B2 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
EP2545048B1 (en) Raltegravir salts and crystalline forms thereof
US20080269499A1 (en) Crystalline forms and process for preparing spiro-hydantoin compounds
CN1582278A (zh) 多晶型rimonabant,其制备方法及含有它的药物组合物
CA2942871A1 (en) Ror-gamma modulators and uses thereof
KR102442536B1 (ko) 리나글립틴 결정형 및 이의 제조방법
CN111511357A (zh) 用于制备他品洛夫的方法
JP2017061578A (ja) 有機化合物
CN1910161A (zh) 1型11－β－羟基甾醇脱氢酶抑制剂的新晶型
EP2093225A1 (en) Process for preparing crystalline eletriptan hydrobromide form ß
WO2008109334A1 (en) Novel crystalline salt form of an antidiabetic compound
WO2023102085A1 (en) Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
JP2012517990A (ja) 結晶質の多形性形態６３１
CN110612291A (zh) 2-([1,2,3]三唑-2-基)-苯甲酸衍生物的制备
JP7205529B2 (ja) オキサゾリジノン化合物の製造方法
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
CN1882526A (zh) 制备伏格列波糖的方法
HK1040078A1 (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
EP2155698A1 (en) Novel thermodynamically stable polymorphic form-l of letrozole
US20230271967A1 (en) Solid state forms of fezolinetant and salts thereof
JP2009523806A (ja) （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
TW201722960A (zh) 經取代的氨基吡喃衍生物之晶型
CN1396922A (zh) 制备－6－(－4－氯苯基)－2,2－二甲基－7－苯基－2,3－二氢－1h－吡咯嗪－5－基乙酸的方法
WO2023222103A1 (zh) 一种三嗪二酮类衍生物的晶型及制备方法
CN1082958C (zh) 他唑非隆的另一结晶形态
JP2017524038A (ja) １−イソプロピル−３−｛５−［１−（３−メトキシプロピル）ピペリジン−４−イル］−［１，３，４］オキサジアゾール−２−イル｝−１ｈ−インダゾールオキサレートの大容量製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070207